scholarly journals Long-Term Outcomes of Personalized Stereotactic Ablative Brachytherapy for Recurrent Head and Neck Adenoid Cystic Carcinoma after Surgery or External Beam Radiotherapy: A 9-Year Study

2021 ◽  
Vol 11 (9) ◽  
pp. 839
Author(s):  
Yi Chen ◽  
Jinzhao Dai ◽  
Yuliang Jiang ◽  
Zhe Ji ◽  
Ping Jiang ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Local Control ◽  
External Beam Radiotherapy ◽  
Objective Response ◽  
External Beam ◽  
Long Term Outcomes ◽  
Adenoid Cystic ◽  
Recurrent Head

The management of recurrent head and neck adenoid cystic carcinoma (HNACC) remains a problematic challenge. This study aims to evaluate the long-term outcomes of personalized stereotactic ablative brachytherapy (SABT) as a salvage treatment for recurrent HNACC after surgery or external beam radiotherapy (EBRT). 21 patients with recurrent HNACC after surgery or EBRT successfully underwent iodine-125 (I-125) seed SABT from May 2011 to November 2019. The objective response rate (ORR), disease control rate (DCR), local control time (LCT), overall survival (OS), symptomatic relief and adverse events (AEs) were analyzed. Following SABT, the ORR and DCR were 85.7% and 100%, respectively. The 3-, and 5-year LCT rates were 68.8% and 55.1%, respectively, and the 3- and 5-year OS rates were 85.9% and 66.2%, respectively. Furthermore, univariate analyses showed that higher D90 (>137.1 Gy) was a strong positive prognostic factor of LCT (p < 0.05). The pain disappeared in one patient 3 months after SABT and partial pain improvement was observed in nine patients 1 to 6 months after SABT. Additionally, dyspnea was relieved in one patient with the tumor involving the trachea. The major AEs were mild intraoperative hemorrhage and skin/mucosal toxicities which were generally graded ≤2 and well-tolerated. Personalized SABT was an effective and safe alternative option for recurrent HNACC after the previous failure of surgery or EBRT. The parameter of D90 may influence the local control.

scholarly journals Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation

2017 ◽  
Vol 127 (10) ◽  
pp. 2265-2269 ◽  
Author(s):  
Safina Ali ◽  
Frank L. Palmer ◽  
Nora Katabi ◽  
Nancy Lee ◽  
Jatin P. Shah ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Local Control ◽  
Postoperative Radiation ◽  
Adenoid Cystic

Long-term outcomes with concurrent carboplatin, paclitaxel, and radiation therapy in locally advanced, inoperable head and neck cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6032-6032
Author(s):  
R. L. Ferris ◽  
S. S. Agarwala ◽  
E. Cano ◽  
D. E. Heron ◽  
J. Johnson ◽  
...  
Keyword(s):  
Head And Neck ◽  
External Beam Radiotherapy ◽  
Objective Response ◽  
Locally Advanced ◽  
Tube Feeding ◽  
Stage Iv ◽  
Tube Placement ◽  
Long Term Outcomes ◽  
Brachytherapy Boost

6032 Background: Our goal was to evaluate long-term outcomes of patients with squamous cell carcinoma of the head and neck (SCCHN) treated with carboplatin, paclitaxel, and radiotherapy. Methods: We conducted a phase II trial in inoperable patients with locally advanced SCCHN. Carboplatin 100 mg/m2 and paclitaxel 40 mg/m2 were administered intravenously once a week during external beam radiotherapy (once daily, 180 cGy/fraction) for 6–7 weeks. Interstitial brachytherapy was used as a boost in selected patients with primary malignancies of the oral cavity and the oropharynx. Results: 55 patients were enrolled. 52 patients (95%) had stage IV and 51 (93%) had technically unresectable disease; 62% had an oropharyngeal primary site. 21 patients underwent brachytherapy boost. Grade 3 or 4 mucositis occurred in 30% of patients. One death occurred during treatment; it was related to complications of gastrostomy tube (G-tube) placement. Forty of 50 evaluable patients (80%) had an objective response, with a complete response rate of 52%. With a median follow-up of 69 months years for surviving patients, the 5-year progression-free survival (PFS) was 36% and the 5-year overall survival (OS) was 35%. Two of the 18 long-term survivors of >50 months were G-tube feeding dependent. Patients undergoing brachytherapy boost (n=21) had similar outcomes compared with the rest of the patients. In multivariate analysis, baseline hemoglobin levels and N stage were predictive of survival. Conclusion: Treatment with concurrent carboplatin, paclitaxel and radiation is safe and offers curative potential for poor prognosis patients with locally advanced SCCHN. No significant financial relationships to disclose.

Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer

2018 ◽  
Vol 23 (4) ◽  
pp. 749-756 ◽  
Author(s):  
Rihito Aizawa ◽  
Kenji Takayama ◽  
Kiyonao Nakamura ◽  
Takahiro Inoue ◽  
Takashi Kobayashi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Castration Resistant Prostate Cancer ◽  
Long Term Outcomes ◽  
Castration Resistant

PO-1036: Intraoperative HDR brachytherapy and external beam radiotherapy for prostate cancer: long-term outcomes

2014 ◽  
Vol 111 ◽  
pp. S158-S159
Author(s):  
R. Galalae ◽  
N. Brüske ◽  
F. Geiger ◽  
F.A. Siebert ◽  
P. Jiang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
External Beam Radiotherapy ◽  
External Beam ◽  
Hdr Brachytherapy ◽  
Long Term Outcomes
Sign in / Sign up

Export Citation Format

Share Document